Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database-Reference-Cited by-同舟云学术

Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database

Published:2023-06-06 Issue:5 Volume:37 Page:699-707
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Pauline Orhon,Robert Marion,Bernardeau Claire,Hlavaty Alex,Fusaroli Michele,Roustit Matthieu,Cracowski Jean-Luc,Khouri Charles^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-023-00603-8.pdf

Reference36 articles.

1. European Medicines Agency. Biosimilar medicines: overview. 2018. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview. Accessed 2 Dec 2022.

2. Biosimilar product information. FDA; 2022. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed 2 Dec 2022

3. Jourdain H, Hoisnard L, Sbidian E, Zureik M. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System. Sci Rep. 2022;12:19569.

4. Afzali A, Furtner D, Melsheimer R, Molloy PJ. The automatic substitution of biosimilars: definitions of interchangeability are not interchangeable. Adv Ther. 2021;38:2077–93.

5. Biosimilars in the EU: information guide for healthcare professionals. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcareprofessionals_en.pdf Accessed 2 Dec 2022.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Hidden Toll of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System;2023-11-17

2. Switching TNF-α inhibitors causes AEs and symptoms related to underlying disease;Reactions Weekly;2023-07-01